Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain
about
Cost-effectiveness analysis of fesoterodine flexible dose in newly diagnosed patients with overactive bladder in routine clinical practice in Spain.Impact of Loss of Work Productivity in Patients with Overactive Bladder Treated with Antimuscarinics in Spain: Study in Routine Clinical Practice Conditions.Third-line treatment for overactive bladder: should mirabegron be tried before intravesical botulinum toxin A therapy?
P2860
Health economics perspective of fesoterodine, tolterodine or solifenacin as first-time therapy for overactive bladder syndrome in the primary care setting in Spain
description
2013 nî lūn-bûn
@nan
2013 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Health economics perspective o ...... primary care setting in Spain
@ast
Health economics perspective o ...... primary care setting in Spain
@en
Health economics perspective o ...... primary care setting in Spain.
@nl
type
label
Health economics perspective o ...... primary care setting in Spain
@ast
Health economics perspective o ...... primary care setting in Spain
@en
Health economics perspective o ...... primary care setting in Spain.
@nl
prefLabel
Health economics perspective o ...... primary care setting in Spain
@ast
Health economics perspective o ...... primary care setting in Spain
@en
Health economics perspective o ...... primary care setting in Spain.
@nl
P2093
P2860
P356
P1433
P1476
Health economics perspective o ...... primary care setting in Spain
@en
P2093
Alba Aguado-Jodar
Amador Ruiz-Torrejón
Antoni Sicras-Mainar
Javier Rejas
Jordi Ibáñez-Nolla
Marion Kvasz
Ruth Navarro-Artieda
P2860
P2888
P356
10.1186/1471-2490-13-51
P577
2013-10-21T00:00:00Z
P5875
P6179
1011352346